Ralliant (NYSE:RAL) SVP Karen Bick Sells 5,485 Shares

Ralliant Corporation (NYSE:RAL) SVP Karen Bick sold 5,485 shares of the business’s stock in a transaction on Tuesday, March 3rd. The shares were sold at an average price of $45.00, for a total transaction of $246,825.00. Following the sale, the senior vice president directly owned 46,756 shares of the company’s stock, valued at $2,104,020. This represents a 10.50% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Ralliant Trading Down 1.4%

RAL stock traded down $0.64 during trading on Thursday, hitting $46.36. The company had a trading volume of 2,098,887 shares, compared to its average volume of 2,052,811. Ralliant Corporation has a 52-week low of $37.27 and a 52-week high of $57.02. The company has a 50 day simple moving average of $49.18 and a 200-day simple moving average of $46.63. The firm has a market capitalization of $5.18 billion and a P/E ratio of 23.65. The company has a quick ratio of 0.58, a current ratio of 0.84 and a debt-to-equity ratio of 0.38.

Ralliant (NYSE:RAL) last released its quarterly earnings data on Wednesday, February 4th. The company reported $0.69 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.67 by $0.02. The company had revenue of $554.60 million during the quarter, compared to analysts’ expectations of $543.04 million. Ralliant’s revenue for the quarter was up 1.2% on a year-over-year basis. Ralliant has set its Q1 2026 guidance at 0.460-0.520 EPS and its FY 2026 guidance at 2.220-2.420 EPS.

Ralliant Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, March 23rd. Shareholders of record on Monday, March 9th will be issued a dividend of $0.05 per share. This represents a $0.20 annualized dividend and a yield of 0.4%. The ex-dividend date is Monday, March 9th. Ralliant’s dividend payout ratio (DPR) is presently 10.20%.

Institutional Trading of Ralliant

Several hedge funds have recently modified their holdings of the company. Dodge & Cox purchased a new position in shares of Ralliant in the 2nd quarter worth approximately $523,571,000. Viking Global Investors LP acquired a new stake in Ralliant in the second quarter valued at approximately $257,200,000. State Street Corp purchased a new position in Ralliant in the second quarter worth $213,096,000. Flossbach Von Storch SE acquired a new position in shares of Ralliant during the second quarter worth $198,077,000. Finally, Millennium Management LLC increased its position in shares of Ralliant by 172.4% during the fourth quarter. Millennium Management LLC now owns 4,973,001 shares of the company’s stock worth $253,175,000 after purchasing an additional 3,147,660 shares in the last quarter.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on RAL shares. Oppenheimer dropped their price target on Ralliant from $60.00 to $50.00 and set an “outperform” rating on the stock in a research report on Friday, February 6th. Truist Financial dropped their target price on shares of Ralliant from $62.00 to $49.00 and set a “buy” rating on the stock in a report on Friday, February 6th. Vertical Research raised shares of Ralliant from a “hold” rating to a “buy” rating and set a $45.00 target price on the stock in a research report on Friday, February 6th. Citigroup lowered their price target on shares of Ralliant from $61.00 to $51.00 and set a “buy” rating for the company in a research report on Friday, February 6th. Finally, Barclays dropped their price objective on shares of Ralliant from $60.00 to $52.00 and set an “overweight” rating on the stock in a research note on Monday, February 9th. Seven equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $50.50.

Ralliant Company Profile

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.